ArticleEndocrine, metabolic & immune disorders drug targets2026
Integrative Analysis of Metabolomic and Transcriptomic Data Reveals Metabolic Signatures and Major Metabolic Pathways in Primary Aldosteronism
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrimary aldosteronism (PA) is the most common secondary hypertension. In this study, we performed the pathway enrichment analysis based on metabolomics and transcriptomic data to find the metabolic perturbations in PA, which could provide new targets for PA and further understand the biology of PA.
methods24 PA patients and 24 healthy adults served as the control group in this study. Six participants were chosen from each group to have their peripheral blood and serum samples analyzed for omics investigations. Another eighteen participants' peripheral blood samples were selected for further validation of the RNA-sequencing results.
resultsTranscriptomic analyses found 518 differentially expressed genes (DEGs), and 339 remarkably differential metabolites (DMs) were identified by untargeted metabolomics. The pathway enrichment analysis was performed by combining with the omics analysis data. We also focused on analyzing metabolic pathways that repeatedly occur and constructed possible genemetabolic networks. A total of 5 genes and 11 metabolites showed significant changes in altered 3 lipid metabolic pathways. Furthermore, the expressions of these genes were verified by qRT-PCR.
conclusionThe combination of metabolomic and transcriptomic data can give a comprehensive picture of unique illness markers and preliminary knowledge of the molecular abnormalities underpinning PA. These findings may point to viable targets for creating treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.